CNS Biomarkers, Amyloid Beta Therapeutics, and Calcineurin Inhibitors Markets: Growth Projections to 2035

The global CNS biomarkers market is projected to grow from USD 8.81 billion in 2026 to approximately USD 26.13 billion by 2035, expanding at a CAGR of 12.90%. The global amyloid beta therapeutics market is predicted to increase from USD 6.12 billion in 2026 to approximately USD 26.50 billion by 2035, at a CAGR of 17.80%. The global calcineurin inhibitors market is forecast to rise from USD 11.17 billion in 2026 to approximately USD 20.88 billion by 2035, at a CAGR of 7.20%.

The CNS biomarkers market is driven by the increasing use of CNS biomarkers, the growing need for understanding various neurological disorders, and rapid advancements in biomarker technologies. Central nervous system (CNS) biomarkers are measurable biological indicators that objectively indicate normal brain/spinal cord function, pathogenic processes, or responses to therapy. They are crucial for diagnosing, monitoring, and treating neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, and Parkinson's disease. Several pharmaceutical companies are increasingly investing in biomarker research to streamline drug development and improve treatment outcomes.

North America dominated the global CNS biomarkers market with a share of 41% in 2025, while Asia-Pacific is expected to grow at the fastest CAGR of 16.8% during the forecast period. By biomarker type, the protein biomarkers segment held a major market share of 42% in 2025, and the genetic biomarkers segment is expected to grow at the fastest CAGR of 15% between 2026 and 2035. By technology, the immunoassays segment accounted for a revenue share of 30% in 2025, while the AI and bioinformatics-based analysis segment is expected to grow at the highest CAGR of 20.5% between 2026 and 2035. By application, the Alzheimer's disease segment led the global market with a share of 32% in 2025 and is expected to grow at the fastest CAGR of 15.5% between 2026 and 2035. By sample type, the blood segment contributed the highest market share of 65% in 2025 and is expected to further grow at the fastest CAGR of 16.5% during the forecast period.

The integration of artificial intelligence (AI) into the CNS biomarkers market is improving patient stratification, enhancing early diagnosis, and streamlining drug development for CNS diseases. AI and machine learning integration into biomarker discovery processes can enhance the accuracy and efficiency of identifying potential candidates for clinical use. AI algorithms can improve diagnostic accuracy in analyzing MRI, CT, and PET scans, enabling the detection of neurodegenerative conditions at earlier stages.

The amyloid beta therapeutics market is driven by rising Alzheimer's cases and demand for safer targeted therapies. The market is intended to focus on the development and commercialization of medications targeting amyloid beta protein buildup in the brain, one of the fundamental pathological markers of Alzheimer's disease. The goal of these therapeutics is to decrease, prevent, or eliminate amyloid plaques and thus arrest or decrease cognitive decline. Market growth is also driven by the rising elderly population, educated awareness about neurodegenerative diseases, favorable reimbursement policies in developed markets, growing demand for early diagnostic screening, and a large clinical pipeline.

North America dominated the global amyloid beta therapeutics market with a 46% share in 2025, and Asia-Pacific is expected to grow at the fastest CAGR of 22% during the forecast period. By therapeutic type, the monoclonal antibodies segment held a dominant position with 48% of the market share in 2025, while the combination therapies segment is expected to grow at the fastest CAGR of 21.5% between 2026 and 2035. By indication, the Alzheimer's disease segment accounted for a 62% revenue share in 2025 and is expected to expand at a CAGR of 18.5% during the forecast period. By mechanism of action, the amyloid plaque clearance segment led with a 40% share in 2025 and is expected to grow at the highest CAGR of 20%. By route of administration, the intravenous segment accounted for a 56% revenue share in 2025. By end-use, the hospitals segment accounted for a 42% share in 2025, while the pharmaceutical and biotechnology companies segment is expected to grow at the fastest CAGR of 24% between 2026 and 2035.

AI tools are enabling researchers to analyze large volumes of data surrounding the behavior of amyloid beta in patients, disease progression, and responses to treatments, helping to more effectively identify novel therapeutic targets. AI-based predictive analysis and real-world data analysis are guiding the understanding of disease mechanisms.

The calcineurin inhibitors market growth is attributed to rising organ transplant procedures, increasing prevalence of autoimmune disorders, and expanding adoption of long-term immunosuppressive therapies. According to the Global Observatory on Donation and Transplantation (GODT) 2026 report, over 173,000 solid organ transplants take place across the globe every year. Calcineurin inhibitors including tacrolimus and cyclosporine help to avoid graft rejection by inhibiting the activation of T-cells that depend on calcineurin and preventing the development of an immune response.

North America dominated the calcineurin inhibitors market with 38.4% of the market share in 2025, while Asia Pacific is expected to grow at the fastest CAGR of 7.6% between 2026 and 2035. By drug type, the tacrolimus segment contributed the highest market share of 48.7% in 2025. By route of administration, the oral segment held a major market share of 52.4% in 2025. By application, the organ transplantation segment captured the highest market share of 46.3% in 2025. By distribution channel, the hospital pharmacies segment generated the biggest market share of 49.6% in 2025. By end user, the hospitals segment accounted for the largest market share of 55.8% in 2025.

AI is changing the calcineurin inhibitors market by enhancing drug development, clinical decision-making, and long-term care of patients. With AI-based molecular simulation tools, companies are able to design next-generation tacrolimus and voclosporin analogs with greater selectivity and lower nephrotoxicity. Machine learning systems are used to predict interactions in calcineurin pathways by analyzing large biochemical datasets to help scientists reduce the preclinical timeline.